Table 1: Summary of completed NSCLC immuno-therapy trials.

Immuno-therapy

Target

Pt No.

Stage

Results

Stage I-III disease

 MAGE-A3

MAGE-A3

182

IB/II following complete resection

HR for DFS = 0.76 (95% CI: 0.48-1.21), HR for OS = 0.81 (95% CI: 0.47-1.40) with MAGE-A3 compared to SOC [5]

Stage III B-IV disease

 BLP-25

MUC1

171

IIIB/IV after 1st line chemotherapy

3 yr. OS 31% for BLP-25 and 17% for BSC (P = 0.035)
Stage IIIB subset MS 30.6 months for BLP-25 vs. 13.3 months for BSC (HR = 0.548, 95% CI: 0.301-0.999) [6,7]

 Belagenpimatucel-L

TGF-β2

75

II/IIIA/IIIB/IV after completion of therapy

Superior MS for high vaccine doses group vs. low vaccine doses group (P = 0.0069) [8]

 EGF

Epidermal growth factor

80

IIIB/IV after first-line chemotherapy

MS 11.7 months with GAR and 3.6 months with PAR (P = 0.0002) [9]

 TG4010

MUC1

148

IIIB/IV with 1st line chemotherapy

6-months PFS 43.2% for TG4010 vs. 35.1% for chemotherapy alone (P = 0.307) [10]

 Ipilimumab

CTLA-4

204

IIIB/IV or recurrent disease in combination with first-line chemotherapy

Immune-related PFS 5.7 months for phased ipilimumab + chemotherapy vs. 4.6 months for placebo + chemotherapy (HR 0.72; P = 0.05) [11]

 Nivolumab

PD-1

296 (122 NSCLC)

IV after completion of first-line chemotherapy

OR in 6 (33%) out of 18 with squamous cell histology; OR in 7 (12%) out of 56 with non-squamous histology [12]

 BMS-936559

PD-L1

207 (75 NSCLC)

IV after completion of first-line chemotherapy

OR in 4 (11%) of 36 non-squamous histology; OR in 1 (8%) of 13 squamous histology [13]

BSC: Best Supportive Care; GAR: Good Antibody Response; HR: Hazard Ration; MS: Median Survival; NSCLC: Non-Small Cell Lung Cancer; OR: Overall Response; PAR: Poor Antibody Response; PFS: Progression-Free Survival; Pt: Patients; RR: Response Rate; SOC: Standard of Care